Arix Bioscience is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Differentiated proposition

Biotech ventures for public markets

Arix provides public market investors access to game-changing life science innovation across a range of therapeutic areas.

Hands on support

We provide more than just capital when we invest. We regularly take a board seat and play an active role to support our companies growth. We provide scientific and commercial experience to help navigate clinical and operational hurdles.

Extensive global networks

Premium access to innovation through transatlantic team and high quality, global venture capital and biotech networks.

Focused model

Late pre-clinical to clinical stage ventures in cutting edge therapeutics with meaningful upcoming value inflection points provide risk-adjusted investments.


Transatlantic Reach

Our transatlantic team provide access to the most promising opportunities in Europe and North America with wide scientific networks and a deep understanding of the industries and markets in which we invest. With access to these networks, Arix is able to provide significant expertise as well as capital to our portfolio companies as they become global leaders in the development and solution of many diseases.

Business Model

Our primary business objective is to focus on the sourcing, financing and development of innovative technologies


We actively manage the portfolio and exit companies once optimum value has been achieved
Capital is recycled onto the balance sheet to be reinvested in new opportunities, creating a
sustainable model for the future


We take a hands-on approach to investing; typically taking a Board seat enables us to help guide the strategy that positions our companies for growth and clinical success
Our portfolio companies get access to our global networks and the flexible, long-term capital they need to grow
We have the experience to navigate scientific and commercial hurdles, mitigating risk for our shareholders


Experienced team with ability to source the best life science innovation opportunities
Extensive global networks enable easy access to the most innovative biotech entrepreneurs


Thorough due diligence to evaluate scientific and commercial opportunity for both new and follow-on investments
Invest in breakthrough science innovation with a clear commercial pathway and market opportunity


Focused on late pre-clinical to clinical stage companies in a range of therapeutic areas to provide a diverse portfolio of companies
Leading deals or co-leading with fellow top-tier investors

How We Source

Arix has developed a wide network within the venture capital and biotech industries. Through this network, Arix is able to identify new technologies and discoveries that provide a rich pipeline of potential investments.

Academic and research

Academic and research

Biotech networks

Biotech networks

Venture capital networks

Venture capital networks